Researchers Developed BioTAK Diagnostic Score
A new diagnostic tool accurately identifies Takotsubo syndrome in patients before they undergo cardiac catheterization.
Updated on Sept. 21, 2026 in Heart Disease
Live Poll
Do you trust new biomarker testing to help you avoid unnecessary medical procedures?
In a 2026 study, researchers developed BioTAK, a diagnostic score that identifies Takotsubo syndrome among patients presenting with suspected heart attacks. The tool helps distinguish the syndrome from acute coronary events before invasive procedures.
Why it matters
Takotsubo syndrome and heart attacks often present with identical symptoms, necessitating invasive catheterization to differentiate the two. BioTAK offers a way to screen patients, potentially reducing the need for these procedures.
The study analyzed 3,165 patients, finding that Takotsubo syndrome accounts for 4% of suspected heart attacks and 10% of women with acute coronary syndrome. The BioTAK score correctly classifies nearly 90% of cases.
The players
University of Zurich
This academic institution served as the research center where the diagnostic score was developed.
King's College London
This university is the institutional affiliation of the lead researcher on the study.
University of Oxford
This institution is the home of the study's co-first author.
The details
Researchers utilized machine learning to identify specific biomarkers, creating a five-item score that incorporates data on heart stress, anxiety regulation, plaque instability, and patient sex. This approach specifically targets the syndrome, which is frequently triggered by significant emotional or physical stress and predominantly impacts postmenopausal women.
Timeline
The findings were published in the Euro Heart Journal in 2026.
The Big Picture
This development follows the precedent set by clinical research in the Euro Heart Journal by providing a novel, non-invasive metric for differential diagnosis. It marks a shift toward using machine learning for rapid, pre-procedural identification of heart-related conditions.
The use of BioTAK could allow patients to avoid unnecessary invasive cardiac catheterizations by identifying Takotsubo syndrome earlier. This change may streamline emergency treatment protocols for individuals presenting with stress-induced cardiac symptoms.
The takeaway
Takotsubo syndrome often mimics severe heart attacks, making accurate and rapid diagnosis essential for patient safety. Adopting non-invasive scoring systems like BioTAK can help clinicians better prioritize patients for the most appropriate cardiac procedures.
Further reading
For more information on diagnostic advancements, visit Heart Disease.
More information
Review the full findings in the Euro Heart Journal peer-reviewed study.
Source note: This article includes information reported by Technology Networks.
Live Poll
Do you trust new biomarker testing to help you avoid unnecessary medical procedures?
